Ruth Langley
Overview
Explore the profile of Ruth Langley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ronellenfitsch U, Friedrichs J, Barbier E, Bass G, Burmeister B, Cunningham D, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2425581.
PMID: 39093560
Importance: The prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative...
2.
Petrucci G, Hatem D, Langley R, Cleary S, Gentry-Maharaj A, Pitocco D, et al.
Sci Rep
. 2024 Mar;
14(1):5546.
PMID: 38448541
Biological samples are often frozen and stored for years and/or thawed multiple times, thus assessing their stability on long-term storage and repeated freeze-thaw cycles is crucial. The study aims were...
3.
Aggarwal A, Court L, Hoskin P, Jacques I, Kroiss M, Laskar S, et al.
BMJ Open
. 2023 Dec;
13(12):e077253.
PMID: 38149419
Introduction: Fifty per cent of patients with cancer require radiotherapy during their disease course, however, only 10%-40% of patients in low-income and middle-income countries (LMICs) have access to it. A...
4.
Bouche G, Langley R, Rush H, Parmar M, Gilbert D
Eur J Cancer
. 2022 Nov;
178:88-90.
PMID: 36427393
No abstract available.
5.
Love S, Cafferty F, Snowdon C, Carty K, Savage J, Pallmann P, et al.
Trials
. 2022 Sep;
23(1):757.
PMID: 36068599
Background: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively...
6.
Faron M, Cheugoua-Zanetsie A, Thirion P, Nankivell M, Winter K, Cunningham D, et al.
Eur J Cancer
. 2021 Sep;
157:278-290.
PMID: 34555647
Introduction: Which neoadjuvant treatment for locally advanced thoracic oesophagus (TE) or gastro-oesophageal junction carcinoma is best remains an open question. Randomised controlled trials variously accrued patients with adenocarcinoma and squamous...
7.
Ranganathan P, Chinnaswamy G, Sengar M, Gadgil D, Thiagarajan S, Bhargava B, et al.
Lancet Oncol
. 2021 Jul;
22(8):e369-e376.
PMID: 34216541
Low-income and middle-income countries (LMICs) have a disproportionately high burden of cancer and cancer mortality. The unique barriers to optimum cancer care in these regions necessitate context-specific research. The conduct...
8.
Walker J, Cattaneo M, Badimon L, Agnelli G, Chan A, Lanas A, et al.
Ecancermedicalscience
. 2020 Mar;
14:998.
PMID: 32153653
At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the...
9.
Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K, et al.
Lancet Gastroenterol Hepatol
. 2019 Sep;
4(11):854-862.
PMID: 31477558
Background: Preclinical, epidemiological, and randomised data indicate that aspirin might prevent tumour development and metastasis, leading to reduced cancer mortality, particularly for gastro-oesophageal and colorectal cancer. Randomised trials evaluating aspirin...
10.
Schiavone F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, et al.
Trials
. 2019 May;
20(1):264.
PMID: 31138317
Background: There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research...